Clinical Trial Update: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, effectiveness and tolerable dose of Arlocabtagene Autoleucel (BMS-986393) in novel combination regimens for relapsed/refr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Arlocabtagene Autoleucel (BMS-986393)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING